> Lynparza in combination with standard-ofcare abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival versus abiraterone alone as a with metastatic castration-resistant prostate cancer with or without homologous recombination repair (HRR) gene mutations in the PROpel Phase III trial.